Spirulina for Hypertension

Verdict: A modest but consistent blood-pressure benefit

Spirulina shows a small, consistent ability to lower blood pressure across four meta-analyses, but the effect is modest and no health agency or clinical society endorses it for hypertension. It may be a minor adjunct, never a replacement for proven treatment.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This earns a preliminary-evidence (B) rating because the four meta-analyses available all point the same direction, yet the signal stays small. A 2025 GRADE-assessed review (PMID 39529406) rated the evidence moderate quality and found spirulina cut systolic pressure by about 4.4 mmHg and diastolic by 2.8 mmHg, with larger drops in people who were hypertensive, overweight, over 50, or supplemented beyond eight weeks. A 35-trial, 1,523-participant analysis (PMID 40953712) and an edible-algae review (PMID 40726022) reported similar reductions of roughly 4-5 mmHg systolic, and an earlier 2021 pooled analysis (PMID 34578932) saw a steeper 9.2 mmHg systolic fall in hypertensive subgroups specifically.

The grade does not reach the top tier for several reasons. The headline effect in mixed populations is only about 4 mmHg, the high-quality trial volume is thin, funding and conflict-of-interest disclosures are largely absent across the analyses, and the included trials vary widely in dose (1-8 g/day) and duration. The promising subgroup results are hypothesis-generating rather than confirmed.

Crucially, the regulatory and clinical picture is silent rather than supportive. The US FDA has only addressed spirulina as a food ingredient (its GRAS notices state the agency had no questions about safety), while the EU, WHO and FAO offer no efficacy or blood-pressure endorsement. Mayo Clinic and Harvard have no dedicated guidance, Cleveland Clinic calls it merely promising, and no hypertension society (AHA, ASH) acknowledges it. Established options like the DASH diet and exercise lower pressure substantially more, so spirulina belongs only as a possible minor adjunct, not a substitute for prescribed care.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.63
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
78%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.55
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.70
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.625
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

The Effect of Spirulina Supplementation on Blood Pressure in Adults: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Clinical Trials
PMID: 39529406 2025 統合分析
Finding: Spirulina supplementation significantly reduced SBP (WMD -4.41 mmHg, 95% CI -6.74 to -2.07) and DBP (WMD -2.84 mmHg, 95% CI -4.65 to -1.03). Subgroup analysis found greater reductions in hypertensive individuals, those with baseline SBP ≥120 / DBP ≥80 mmHg, overweight individuals, those over 50 years, and interventions lasting >8 weeks.
Effect size: WMD SBP -4.41 mmHg; DBP -2.84 mmHg
View on PubMed
Effect of Spirulina Supplementation on Systolic and Diastolic Blood Pressure: Systematic Review and Meta-Analysis of Randomized Controlled Trials
PMID: 34578932 2021 統合分析 n = 230
Finding: Across 5 RCTs (230 subjects for SBP), spirulina significantly reduced SBP (MD -4.59 mmHg, 95% CI -8.20 to -0.99) and DBP (MD -7.02 mmHg, 95% CI -8.86 to -5.18 after excluding one outlier). The hypertensive subgroup showed a markedly larger SBP reduction (MD -9.18 mmHg, 95% CI -14.93 to -3.43) versus the normotensive subgroup (MD -2.26 mmHg).
🟠 Limited quality Effect size: MD SBP -4.59 mmHg (overall); SBP -9.18 mmHg (hypertensive subgroup)
View on PubMed
Spirulina's impacts on cardiovascular health: Insights from a systematic meta-analysis of RCT
PMID: 40953712 2025 統合分析 n = 1,523
Finding: Across 35 trials (45 effect sizes, 1523 participants), spirulina intake significantly decreased SBP (WMD -3.85 mmHg, p=0.002) and DBP (WMD -3.09 mmHg, p<0.001), alongside improvements in glucose homeostasis, lipid profile, anthropometrics and inflammatory markers. Authors conclude spirulina is an adjunct or complementary measure to improve cardiometabolic profiles.
Effect size: WMD SBP -3.85 mmHg; DBP -3.09 mmHg
View on PubMed
Edible Algae Reduce Blood Pressure in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
PMID: 40726022 2025 統合分析
Finding: Among edible algae studied, spirulina was the most effective at lowering blood pressure, reducing SBP by -5.28 mmHg and DBP by -3.56 mmHg. Authors note spirulina administration may have a supportive role in the prevention and treatment of hypertension.
Effect size: WMD SBP -5.28 mmHg; DBP -3.56 mmHg (spirulina subgroup)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
FDA had no questions source↗
L4b EU EFSA
Neutral
L4d TW TFDA / 衛福部
Neutral
食用藻類及其製品應符合「食用藻類衛生標準」之規定。 source↗
L4e WHO
Neutral
A review on culture, production and use of spirulina as food for humans and feeds for domestic animals and fish (FAO Fisheries and Aquaculture Circular No. 1034, 2008). source↗
L5a NIH Office of Dietary Supplements
Cautious
L5c Cleveland Clinic
Neutral
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-hypertension-INT-spirulina-001 繁體中文版 →